|
High Court Likely to Keep ‘Safe Harbor’ Broad, Aiding Generics, Biosimilars
The country’s highest court is likely to mull Hatch-Waxman’s safe-harbor provision now that the U.S. Court of Appeals for the Federal Circuit has issued contradictory rulings on when the law allows drugmakers to use others’ patents without fear of infringement.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives